Lymphazurin

(Isosulfan blue)

Phase 3Small molecule

CCovidien

Lymphazurin is one of 208 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

207

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Endometrial CancerActive, not recruiting

Cervical CancerActive, not recruiting

MetastasesCompleted

Metastatic Colorectal CancerPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

MelanomaPreclinical

Active, not recruiting

Endometrial CancerPreclinical

Active, not recruiting

Cervical CancerPreclinical

Active, not recruiting

MetastasesPreclinical

Completed

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lymphazurin

CCovidien

Phase 3

4 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Breast Cancer

NCT03927027

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

Completed·SStanford University·Phase 2·NCT01771666·23 enrolled

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Completed·UUniversity of Miami·N/A·NCT00450723·39 enrolled

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03927027·534 enrolled

Show 1 more trial

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Completed·MM.D. Anderson Cancer Center·N/A·NCT00438477·74 enrolled

Endometrial Cancer2 trials

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Terminated·—·N/A·NCT01939028·58 enrolled

Lymph Node Mapping in Patients With Endometrial Cancer

Completed·OOhio State University Comprehensive Cancer Center·N/A·NCT01818739·204 enrolled

Metastatic Colorectal Cancer1 trial

Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer

Completed·RRoswell Park Cancer Institute·N/A·NCT00003186

Melanoma1 trial

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

Completed·SStanford University·N/A·NCT01898403·50 enrolled

Cervical Cancer1 trial

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Terminated·GGynecologic Oncology Group·N/A·NCT00070317·102 enrolled

2 more indications

Colorectal Cancer1 trial

Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer

Unknown status·SSaint John's Cancer Institute·Phase 2·NCT00625625·225 enrolled

Metastases1 trial

Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat

Completed·NNYU Langone Health·N/A·NCT00012168

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

LYMPHAZURIN

NDA NDA018310

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Isosulfan blue. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isosulfan blue compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isosulfan blue. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018310). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Covidien company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCovidien

Lymphazurin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Breast Cancer4 trials

Endometrial Cancer2 trials

Metastatic Colorectal Cancer1 trial

Melanoma1 trial

Cervical Cancer1 trial

Colorectal Cancer1 trial

Metastases1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News